Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry
2006; 63: 1217–23.
Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry
2005; 66: 148–58.
Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry
2004; 161: 1256–63.
Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer C. A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol
2007; 21: 684–90.
Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology
2003; 28: 148–52.
Drevets WC. Neuroimaging abnormalities in the amygdala in mood disorders. Ann NY Acad Sci
2003; 985: 420–44.
Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry
2001; 50: 651–8.
Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry
2004; 61: 877–89.
Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry
2006; 59: 816–20.
Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology
2005; 30: 1724–34.
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM–IV Axis I Disorders (SCID–I). American Psychiatric Press, 1997.
Nelson HE, Willison J. National Adult Reading Test (NART). nferNelson, 1991.
Spielberger CD, Gorsuch RL, Lushene RD. Manual for the State–Trait Anxiety Inventory (STAI). Consulting Psychologists Press, 1983.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry
1961; 4: 561–71.
von Zerssen D, Strian F, Schwarz D. Evaluation of depressive states, especially in longitudinal studies. Mod Probl Pharmacopsychiatry
1974; 7: 189–202.
Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol
1988; 54: 1063–70.
Ekman P, Friesen WV. Pictures of Facial Affect. Consulting Psychologists Press, 1976.
Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage
2002; 17: 825–41.
Smith SM. Fast robust automated brain extraction. Hum Brain Mapp
2002; 17: 143–55.
Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal
2001; 5: 143–56.
Beckmann CF, Jenkinson M, Smith SM. General multilevel linear modeling for group analysis in FMRI. Neuroimage
2003; 20: 1052–63.
Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage
2004; 21: 1732–47.
Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab
1992; 12: 900–18.
Talairach J, Tournoux P. Co-Planar Stereotactic Atlas of the Human Brain. Thieme, 1988.
Lancaster JL, Woldroff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, et al. Automated Talairach atlas labels for function brain mapping. Hum Brain Mapp
2000; 10: 120–31.
Bhagwagar Z, Cowen PJ, Goodwin GM, Harmer CJ. Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. Am J Psychiatry
2004; 161: 166–8.
Mogg K, Bradley BP. A cognitive-motivational analysis of anxiety. Behav Res Ther
1998; 36: 809–48.
Morris JS, Frith CD, Perrett DI, Rowland D, Young AW, Calder AJ, et al. A differential neural response in the human amygdala to fearful and happy facial expressions. Nature
1996; 383: 812–5.
Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. J Neurosci
1992; 12: 3628–41.
Rauch SL, Shin LM, Wright CI. Neuroimaging studies of amygdala function in anxiety disorders. Ann NY Acad Sci
2003; 985: 389–410.
Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry
2003; 160: 64–75.
Stutzmann GE, LeDoux JE. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J Neurosci
1999; 19: RC8.
Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol
2002; 12: 527–44.
Kent JM, Coplan JD, Gorman JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry
1998; 44: 812–24.
Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry
2004; 55: 1171–8.
Attenburrow MJ, Williams C, Odontiadis J, Reed A, Powell J, Cowen PJ, et al. Acute administration of nutritionally sourced tryptophan increases fear recognition. Psychopharmacology (Berl)
2003; 169: 104–7.
Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O, et al. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry
2006; 63: 978–86.
Whalen PJ, Rauch SL, Etcoff NL, McInerney SC, Lee MB, Jenike MA. Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. J Neurosci
1998; 18: 411–8.
Phillips ML, Williams LM, Heining M, Herba CM, Russell T, Andrew C, et al. Differential neural responses to overt and covert presentations of facial expressions of fear and disgust. Neuroimage
2004; 21: 1484–96.
Bishop SJ, Duncan J, Lawrence AD. State anxiety modulation of the amygdala response to unattended threat-related stimuli. J Neurosci
2004; 24: 10364–8.
Pessoa L, McKenna M, Gutierrez E, Ungerleider LG. Neural processing of emotional faces requires attention. Proc Natl Acad Sci USA
2002; 99: 11458–63.
Wise RG, Tracey I. The role of fMRI in drug discovery. J Magn ResonImaging
2006; 23: 862–76.
Iannetti GD, Wise RG. BOLD functional MRI in disease and pharmacological studies: room for improvement?
Magn Reson Imaging
2007; 25: 978–88.